Eur Rev Med Pharmacol Sci 2012; 16 (6): 743-746

Eltrombopag – an oral thrombopoietin agonist

V. Sharma, H. Randhawa, A. Sharma, S. Aggarwal

Department of Medicine, University College of Medical Sciences, New Delhi (India)

The therapy for immune thrombocytopenic purpura (ITP) has evolved in the recent past. In certain cases therapy for ITP remains inadequate. Thrombopoietin receptor agonists are the latest addition to the armamentarium to manage the thrombocytopenia. While romiplostim was the first second generation thrombopoietin agonist to become available, eltrombopag is particularly attractive as it is an orally bioavailable agent.

This review focuses on the use, safety and efficacy of eltrombopag in various clinical conditions.

Corresponding Author: Vishal Sharma, MD; e-mail: docvishalsharma@gmail.com

To cite this article

V. Sharma, H. Randhawa, A. Sharma, S. Aggarwal
Eltrombopag – an oral thrombopoietin agonist

Eur Rev Med Pharmacol Sci
Year: 2012
Vol. 16 - N. 6
Pages: 743-746

Keywords Related articles:

  1. Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits
  2. Effects of insulin-oral hypoglycemic agents combined therapy in outpatients with type 2 diabetes
  3. Oral inflammatory process and general health Part 1: The focal infection and the oral inflammatory lesion
  4. Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women
  5. Efficacy and safety of topical Hirudin (Hirudex®): a double-blind, placebo-controlled study